Search

Displaying results 4201 - 4210 of 10000 in total
  1. Drug

    VPM4001

    go.drugbank.com/drugs/DB05089
    Experimental

    It consists of irradiated human LNCaP cells that have been genetically modified to permanently secrete interferon-γ and interleukin-2 (LNCaP/IL-2/IFN-γ). … Interferon-γ enhances presentation of tumour antigens, whereas interleukin-2 stimulates T cells.

  2. Drug

    Pyruvaldehyde

    go.drugbank.com/drugs/DB03587
    Experimental

    An organic compound used often as a reagent in organic synthesis, as a flavoring agent, and in tanning. … It has been demonstrated as an intermediate in the metabolism of acetone and its derivatives in isolated cell preparations, in various culture media, and in vivo in certain animals. [PubChem]

    Synonyms: 2-oxopropanal, 2-ketopropionaldehyde
  3. Drug

    L-cysteic acid

    go.drugbank.com/drugs/DB03661
    Experimental

    L-cysteic acid is a beta-sulfoalanine. It is an amino acid with a C-terminal sulfonic acid group which has been isolated from human hair oxidized with permanganate.

    Synonyms: 3-sulfo-L-alanine, 2-Amino-3-sulfopropionic acid
  4. Drug

    Maropitant

    go.drugbank.com/drugs/DB11427
    ExperimentalVet approved

    Maropitant, used as maropitant citrate, is a neurokinin receptor antagonist, which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs. … It was approved by the FDA in 2007 for use in dogs, and more recently has also been approved for use in cats.

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  5. Drug

    Mitometh

    go.drugbank.com/drugs/DB12117
    Investigational

    Mitometh has been investigated for the treatment of Lung Neoplasms, Untreated Childhood Medulloblastoma, and Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor.

  6. Drug

    Sonepcizumab

    go.drugbank.com/drugs/DB06305
    Investigational

    S1P is the extracellular ligand for the G protein-coupled lysophospholipid receptor EDG-1 (endothelial differentiation gene-1). … A humanized monoclonal antibody directed against sphingosine 1-phosphate (S1P) with potential antiangiogenic and antineoplastic activities.

  7. Drug

    CP-39,332

    go.drugbank.com/drugs/DB09193
    Experimental

    However, none of the members of this stereoisomers has been marketed. … CP-39,332 is a serotonin-norepinephrine reuptake inhibitor (SNRI).

  8. Drug

    Cimetropium

    go.drugbank.com/drugs/DB09271
    Investigational

    It is also endowed of a direct myolitic action which partially accounts for its antispasmodic activity. It has never been approved for use in the U.S. or Canada. … Cimetropium is a semi-synthetic belladonna alkaloid and derivative of scopolamine. It is a potent antimuscarinic and an effective antispasmodic drug.

  9. Drug

    WNY0824

    go.drugbank.com/drugs/DB23606
    Experimental

    [A274253] It is a dual inhibitor of PLK-1 and BRET-4, which have both been found to be involved in CRPC via suppression of AR/MYC-mediated transcription. [A274258] … WNY0824 is a preclinical small molecule drug being investigated for the treatment of Castration-Resistant Prostrate Cancer (CRPC).

    Synonyms: PLK1/BRD4-IN-1
  10. Drug

    L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal

    go.drugbank.com/drugs/DB06124
    Experimental

    C-101 includes a carnitine carrier molecule and a leupeptin analogue, a known calpain inhibitor. Calpain is the primary protease that degrades skeletal muscle. … C-101, also called Myodur, is developed for the treatment of Duchenne’s muscular dystrophy (DMD) which is a morbid genetic disease that can lead to death in late adolescence due to accelerated skeletal